Ventana Biotech Inc (VNTA) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Ventana Biotech Inc $0.03, price $0.05, upside -29.0%, quality 93 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Ventana Biotech Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 22, 2026.
How to read this chart
60‑month range $0.0005 – $0.2810 · fair‑value band $0.0299 – $0.0348 · the $0.0490 price screens above the $0.0348 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 22, 2026.
Follow Ventana Biotech in your weekly email
Every Wednesday you see whether Ventana Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ventana Global Inc. provides various portfolio of loans. The company offers custom financial, borrower and lender network, business advising and mentoring, and cash flow services. It also provides consulting services to third party businesses and individuals. The company was formerly known as Ventana Biotech, Inc. and changed its name to Ventana Global Inc.
Show more
Ventana Global Inc. provides various portfolio of loans. The company offers custom financial, borrower and lender network, business advising and mentoring, and cash flow services. It also provides consulting services to third party businesses and individuals. The company was formerly known as Ventana Biotech, Inc. and changed its name to Ventana Global Inc. in January 2015. Ventana Global Inc. is headquartered in Denver, Colorado.
Stock analysis
Ventana Biotech Inc (VNTA) currently trades at $0.0490, while our model-based Fair Value estimate is $0.0348, implying the stock looks roughly 40.8% overvalued today.
Show more
Valuation
Bull case: the Earnings-Based group reads highest at a median of $0.0600 per share, and 2 of the 3 models we run sit above the $0.0490 price.
Bear case: the Multiples group reads lowest at $0.0200, and 1 of the 3 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.0299 (bear) to $0.0348 (bull), the price of $0.0490 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 93/100 (high quality), in the Financial Services sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Ventana Biotech Inc reported revenue of $115K in FY2026 versus $0 in FY2008. Reported net income was $86.1K in FY2026.
Key figures
Market cap $2.6M · EPS (TTM) $−0.0010 · Net margin 75.2% · Return on assets (EBIT) 44.0% · Net debt $47.6K.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 126% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −32% fair-value upside, at −29%, VNTA screens cheaper than that median.
Fair Value models
Bear $0.0299Fair Value $0.0348Bull $0.0348
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.51/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
≈ +70.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+70.8%
Dividend (yield on the price)0.0%
⚠ Approximate: the rate leans on 2026, which sits 363% above its own trend.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Credit Services · 331 stocks
Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score92 · Top 25%
Fair Value upside−29% · Below median
Profitability
Return on equity (TTM)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets0% · Bottom 25%
Net margin (TTM)75% · Top 25%
Operating margin (TTM)0% · Bottom 25%
Growth and dividend
Revenue growth0% · Below median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Credit Services median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Ventana Biotech Inc (VNTA) overvalued or undervalued?
As of Aug 22, 2026, our model estimates a fair value of $0.0348 versus a price of $0.0490, about −29% upside (overvalued).
What is the fair value of VNTA?
Our model-based fair value for Ventana Biotech Inc is $0.0348 (as of Aug 22, 2026), built from audited fundamentals. The current price: $0.0490.
What is the quality score of VNTA?
Ventana Biotech Inc has a Quality Score of 93/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ventana Biotech Inc (VNTA)?
Our model-based price target is the fair value of $0.0348 (as of Aug 22, 2026) from 3 valuation models. Cautious scenario $0.0299, optimistic scenario $0.0348. It is a calculation from audited fundamentals, not an analyst target.
What is the Ventana Biotech Inc stock forecast for 2026?
Our models put fair value at $0.0348, about −29% upside versus a price of $0.0490 (overvalued). Cautious scenario $0.0299, optimistic scenario $0.0348. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Ventana Biotech Inc (VNTA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ventana Biotech Inc it is $0.0348 per share (as of Aug 22, 2026), against a price of $0.0490. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Ventana Biotech Inc stock overvalued or undervalued in 2026?
As of Aug 22, 2026, VNTA trades above its calculated fair value: price $0.0490, fair value $0.0348, a gap of about −29% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VNTA?
No. The price is what the market pays today ($0.0490); the fair value is what the company's own numbers justify ($0.0348). For Ventana Biotech Inc the two are $0.0142 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ventana Biotech Inc worth?
The market values Ventana Biotech Inc at about $2.6M (market capitalisation, as of Aug 22, 2026). Per share that is $0.0490; our models calculate a fair value of $0.0348 per share.
What do the bullish and bearish scenarios say about VNTA?
Our models span a range for Ventana Biotech Inc: cautious scenario $0.0299, base $0.0348, optimistic $0.0348 per share (as of Aug 22, 2026, price $0.0490). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ventana Biotech Inc (VNTA)?
Balance-sheet figures for Ventana Biotech Inc (as of Aug 22, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 93/100, which measures business quality independently of the share price.
How far is VNTA from its 52-week high?
Ventana Biotech Inc trades at $0.0490, about 42% below its 52-week high of $0.0849 and 126% above the low of $0.0217 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0348 is for.
Which stocks are comparable to Ventana Biotech Inc?
From the same area (Financial Services) we also value Visa Inc, Mastercard Incorporated, American Express Company, Capital One Financial Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ventana Biotech Inc stock attractive at the current price?
The data as of Aug 22, 2026: price $0.0490, calculated fair value $0.0348 (−29%), Quality Score 93/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VNTA calculated?
We run Ventana Biotech Inc through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0348, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Ventana Biotech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ventana Biotech Inc (VNTA)?
The closing price on Sep 22, 2026 was $0.0490. Our model-based fair value is $0.0348, about −29% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ventana Biotech Inc right now?
A high-quality business (quality 93/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety. The price sits above even our optimistic bull case ($0.0348). The favourable scenario is already priced in. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Key figures of Ventana Biotech Inc
How large is the market capitalisation of Ventana Biotech Inc (VNTA)?
The market capitalisation of Ventana Biotech Inc is $2.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Ventana Biotech Inc (VNTA)?
Earnings per share at Ventana Biotech Inc are $−0.0010. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Ventana Biotech Inc (VNTA)?
The net margin of Ventana Biotech Inc is 75.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Ventana Biotech Inc (VNTA)?
On an EBIT basis the return on assets of Ventana Biotech Inc is 44.0% (avg 2y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much net debt does Ventana Biotech Inc (VNTA) carry?
The net debt of Ventana Biotech Inc is $47.6K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ventana Biotech Inc in the live analysis
One click puts Ventana Biotech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Aug 22, 2026